Last reviewed · How we verify
Riboxamide (tiazofurine)
Riboxamide (generic name: tiazofurine) is a tiazofurine drug. It is currently in unknown development.
Riboxamide works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis.
Riboxamide is a small molecule that inhibits the enzyme IMP dehydrogenase. It was investigated for potential use in cancer treatment, but its development was halted due to side effects, and it may also have antiviral effects.
At a glance
| Generic name | tiazofurine |
|---|---|
| Drug class | tiazofurine |
| Therapeutic area | Oncology |
| Phase | unknown |
Mechanism of action
Imagine your body's cells are constantly making new copies of their DNA. Riboxamide gets in the way of this process by blocking an enzyme that helps build new DNA. This can prevent cancer cells from growing and dividing.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Riboxamide CI brief — competitive landscape report
- Riboxamide updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Riboxamide
What is Riboxamide?
How does Riboxamide work?
What is the generic name of Riboxamide?
What drug class is Riboxamide in?
What development phase is Riboxamide in?
Related
- Drug class: All tiazofurine drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Oncology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing